ACR Congress Review 2019
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Impact of BMI on tofacitinib safety and efficacy in PsA<br />
A post-hoc analysis on the impact of baseline BMI on tofacitinib efficacy and safety in patients with PsA<br />
was presented by Ritchlin and colleagues. Data were pooled from two placebo-controlled, double-blind,<br />
Phase 3 studies in patients with active PsA and an inadequate response to ≥1 csDMARD (OPAL<br />
Broaden) or to ≥1 TNFi (OPAL Beyond). The analysis included 710 patients of whom 43.8% were obese<br />
(BMI ≥ 30). At baseline, 161 patients had a BMI